Update on the clinical use of kinase inhibitors in melanoma

scientific article published in September 2017

Update on the clinical use of kinase inhibitors in melanoma is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1111/DDG.13321
P698PubMed publication ID28872233

P50authorSelma UgurelQ61525329
Jürgen C BeckerQ87595653
Dirk SchadendorfQ32649390
P2093author name stringCathrin Ritter
Ioana Cosgarea
P2860cites workKIT gene mutations and copy number in melanoma subtypesQ46267082
Transient MEK inhibitor-associated retinopathy in metastatic melanoma.Q50455744
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutationsQ24632064
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyQ27276774
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 studyQ27852083
Combined vemurafenib and cobimetinib in BRAF-mutated melanomaQ27853076
Improved overall survival in melanoma with combined dabrafenib and trametinibQ27853091
Hepatotoxicity with combination of vemurafenib and ipilimumabQ28288255
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialQ29614756
COT drives resistance to RAF inhibition through MAP kinase pathway reactivationQ29615032
Somatic activation of KIT in distinct subtypes of melanomaQ34569987
Genomic Classification of Cutaneous MelanomaQ34670776
Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibitionQ36059811
Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathwayQ36109039
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT InhibitionQ37237619
NF1 Mutations Are Common in Desmoplastic MelanomaQ37286915
KIT as a therapeutic target in metastatic melanomaQ37701887
Navigating the therapeutic complexity of PI3K pathway inhibition in melanomaQ38148747
Update on primary mucosal melanoma.Q38210789
Survival of patients with advanced metastatic melanoma: The impact of novel therapiesQ38680472
Developments in targeted therapy in melanomaQ38786472
Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutationsQ38852335
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.Q39212469
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trialQ39537308
Vulvar and vaginal melanoma: A unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma.Q40406211
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.Q40458599
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trialQ40875359
Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumabQ42557008
Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.Q45974368
P433issue9
P304page(s)887-893
P577publication date2017-09-01
P1433published inJDDGQ15753048
P1476titleUpdate on the clinical use of kinase inhibitors in melanoma
P478volume15

Reverse relations

cites work (P2860)
Q46742817Intratumor and Intertumor Heterogeneity in Melanoma
Q93007229Modulating Tumor Cell Functions by Tunable Nanopatterned Ligand Presentation
Q98158998RNAi-mediated IARS2 knockdown inhibits proliferation and promotes apoptosis in human melanoma A375 cells

Search more.